WOCKPHARMA2018-01-012018-03-31in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2018-01-012018-03-31in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2018-01-012018-03-31in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2018-01-012018-03-31in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares WOCKPHARMA 2017-04-01 2018-03-31 2018-04-18 INR Crores Yearly Single segment Pharmaceuticals 2018-01-01 2018-03-31 Audited Standalone 9133400000.00 105600000.00 9239000000.00 1400400000.00 1093700000.00 37300000.00 1236400000.00 421200000.00 272400000.00 2078900000.00 6540300000.00 2698700000.00 0.00 2698700000.00 218900000.00 755400000.00 974300000.00 0.00 1724400000.00 0.00 0.00 0.00 0.00 1724400000.00 10200000.00 1734600000.00 0.00 0.00 553200000.00 5 0.00 0 0.00 15.59 15.41 0.00 0.00 15.59 15.41 Notes To Standalone Results :- n n1. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 04, 2018. The statutory auditors have expressed an unmodified audit opinion with respect to the Audited Financial Results of the Company for the quarter/year ended March 31, 2018. n n2. During the year the Company has alloted 82,425 Equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options. n n3. Subject to the approval of shareholders at the annual general meeting, Board of Directors have recommended dividend of 0.01% (at the rate of Rs. 0.0005 per share of Rs. 5/- each) on 475,659,941 Non-convertible Cumulative Redeemable Preference shares of Rs. 5/- each and 121,454,927 Optionally Convertible Cumulative Redeemable Preference Shares of Rs. 5/- each aggregating to Rs. 298,557/-. n n4. Figures for the quarter ended March 31, 2018 and March 31, 2017 are the balancing figures between the audited figures in respect of the full financial year and the reviewed figures upto the third quarter of the relevant financial year. n n5. The Company is exclusively into Pharmaceutical business Segment. n n6. Previous period / year figures have been recast / re-grouped to conform to the current period's presentation. n nOther notes: nIn Excel Utility(XBRL) of BSE we are unable to find item as Exchange fluctuation (gain)/ loss under Expenses head. Hence, we have mentioned it in other expense. 2017-04-01 2018-03-31 Audited Standalone 24772900000.00 568500000.00 25341400000.00 4571200000.00 3911500000.00 1270900000.00 5064400000.00 1695800000.00 1062400000.00 6726000000.00 24302200000.00 1039200000.00 0.00 1039200000.00 218900000.00 133700000.00 352600000.00 0.00 686600000.00 0.00 0.00 0.00 0.00 686600000.00 -100000.00 686500000.00 0.00 0.00 553200000.00 5 0.00 0 0.00 0.00 6.21 6.14 0.00 0.00 6.21 6.14 Exchange Fluctuation (gain) / loss 15400000.00 Other Expenses 2063500000.00 Exchange Fluctuation (gain) / loss 55100000.00 Other Expenses 6670900000.00 0.00 0.00 0.00